Targeted therapies and immunotherapies are increasingly offering viable alternatives to the chemotherapies that have stood for decades as a mainstay of treatment for individuals living with blood ...
B-cell lymphoma in the 3L+ setting 83% overall response and 61% complete response rates in cohort comprised predominantly of patients with primary refractory large B-cell lymphoma in the 2L setting ...
BeOne Medicines Ltd. , a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy ...
Six of eight responders presented with low bone marrow blast counts at baseline, supporting further investigation in this patient population most likely to benefit from MP0533 ZURICH-SCHLIEREN, ...
Pfizer Inc. (NYSE: PFE)today presented results from the Phase 3 BASIS study (NCT03938792) evaluating HYMPAVZI® (marstacimab) for adults and ...
Palliative care for diffuse large B-cell lymphoma has significantly improved over the past several years, but disparities ...
Black race is an independent prognostic factor for shorter survival in acute myeloid leukemia independent of cytogenetic profiles, according to study results presented at ASH Annual Meeting and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback